Oxcarbazepine Tablet, Film Coated
Product Images NDC 0615-8635

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 0615-8635). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Oxcarbazepine Tabs 8634 8635 8636 1)

Chemical structure of Oxcarbazepine, showing its molecular framework with a ketone group, two benzene rings, and a carboxamide group attached to a bicyclic system.*

FDA Label Image

Logo (Oxcarbazepine Tabs 8634 8635 8636 10)

FDA Label Image

Principal Display Panel (Oxcarbazepine Tabs 8634 8635 8636 11)

Oxcarbazepine Tablets USP 150 mg film-coated oral tablets packaging label with barcodes. The label indicates a quantity of 30 tablets, lot number 8634, and packaging by Vangard Labs, Glasgow, KY. Storage instructions and institutional use notice are included along with multiple barcodes for individual tablets labeled with the same dosage and lot information.*

FDA Label Image

Principal Display Panel (Oxcarbazepine Tabs 8634 8635 8636 12)

Oxcarbazepine Tablets USP 300 mg film-coated tablets label for oral use. The label shows a 30-count package, manufactured by Esjay for ANI Pharmaceuticals and packaged by Vanguard Labs, Glasgow, KY. It includes storage instructions and states the product is for institutional use only.*

FDA Label Image

Principal Display Panel (Oxcarbazepine Tabs 8634 8635 8636 13)

Oxcarbazepine Tablets USP 600 mg film-coated oral tablets label for a 30-count package. The label shows the drug name, dosage strength, lot number, and barcodes. Manufactured by Esjay for ANI Pharmaceuticals and packaged by Vanguard Labs in Glasgow, KY. The label includes storage instructions, contents per tablet, and a section for recording receipt dates and times. Marked for institutional use only.*

FDA Label Image

Fig-1 (Oxcarbazepine Tabs 8634 8635 8636 2)

A Kaplan-Meier survival curve graph illustrating exit rates over time from Day 2 to Day 11 for two treatment groups: Oxcarbazepine and placebo. The y-axis represents the exit rate from 0 to 1.0, and the x-axis shows time on trial in days. The graph includes a log-rank test p-value of 0.0001 indicating statistical comparison between groups.*

FDA Label Image

Fig-2 (Oxcarbazepine Tabs 8634 8635 8636 3)

A line graph showing seizure rate over days from first dose to first seizure in two treatment groups labeled as Treatment and Placebo. The x-axis represents days from first dose to first seizure up to 140, and the y-axis represents seizure rate from 0 to 1. The plot includes a log-rank test p-value of 0.046 comparing the two groups.*

FDA Label Image

Fig-3 (Oxcarbazepine Tabs 8634 8635 8636 4)

A Kaplan-Meier survival curve chart comparing time to exit (days) between two treatment groups labeled HIGH and LOW. The y-axis shows the exit rate ranging from 0.0 to 1.0, and the x-axis shows time to exit up to 130 days. A log-rank test p-value of 0.0001 is displayed on the chart.*

FDA Label Image

Fig-4 (Oxcarbazepine Tabs 8634 8635 8636 5)

A Kaplan-Meier survival curve chart comparing time to exit (in days) between two treatment groups labeled "HIGH" and "LOW." The y-axis shows the exit rate, ranging from 0 to 1, and the x-axis shows time to exit in days, ranging from 0 to 130. The "LOW" group shows a steeper rise in exit rate over time compared to the "HIGH" group. A log-rank test with a p-value of 0.0001 is noted on the chart.*

FDA Label Image

Table-1 (Oxcarbazepine Tabs 8634 8635 8636 6)

A partial text panel listing potential side effects including nausea, tiredness, headache, confusion, and more frequent or severe seizures. The text is in bullet point format and appears to come from a medication information or warning section.*

FDA Label Image

Table-2 (Oxcarbazepine Tabs 8634 8635 8636 7)

A medication facts panel listing potential side effects or symptoms to watch for while taking the drug, including swelling of the face, eyes, lips, or tongue; trouble swallowing or breathing; skin rash; hives; fever; painful sores; yellowing of the skin or eyes; unusual bruising or bleeding; severe fatigue or weakness; severe muscle pain; and frequent infections. The text is presented as bullet points.*

FDA Label Image

Table-3 (Oxcarbazepine Tabs 8634 8635 8636 8)

A partial text panel listing behavioral warning signs related to the drug Oxcarbazepine, including symptoms such as thoughts about suicide, depression, anxiety, panic attacks, insomnia, irritability, aggressive or violent behavior, impulsive actions, mania, and other mood or behavior changes.*

FDA Label Image

Med-guide (Oxcarbazepine Tabs 8634 8635 8636 9)

A text panel listing potential side effects including dizziness, sleepiness, double vision, tiredness, nausea, vomiting, problems with vision, trembling, problems with walking and coordination (unsteadiness), rash, and headache.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.